ANEBULO PHARMACEUTICALS, INC. Prepaid Expense, Current
ANEBULO PHARMACEUTICALS, INC. (ANEB) had Prepaid Expense, Current of $175.41 thousand as of 2025-12-31, per its 10-Q filed 2026-02-12.
Financial Statements › Balance Sheet › Assets › Assets, Current › Prepaid Expense, Current
us-gaap:PrepaidExpenseCurrent · last filed 2026-02-12
- 2025-12-31: Prepaid Expense, Current $175.41K.
- 2025-09-30: Prepaid Expense, Current $170.77K.
- 2025-06-30: Prepaid Expense, Current $261.44K.
- 2025-03-31: Prepaid Expense, Current $528.03K.
| Period end | Prepaid Expense, Current |
|---|---|
| 2025-12-31 | $175.41K 10-Q · filed 2026-02-12 |
| 2025-09-30 | $170.77K 10-Q · filed 2025-11-13 |
| 2025-06-30 | $261.44K 10-Q · filed 2026-02-12 |
| 2025-03-31 | $528.03K 10-Q · filed 2025-05-13 |
| 2024-12-31 | $366.27K 10-Q · filed 2025-02-14 |
| 2024-09-30 | $312.94K 10-Q · filed 2024-11-13 |
| 2024-06-30 | $413.79K 10-K · filed 2025-09-29 |
| 2024-03-31 | $223.68K 10-Q · filed 2024-05-15 |
| 2023-12-31 | $171.74K 10-Q · filed 2024-02-13 |
| 2023-09-30 | $527.31K 10-Q · filed 2023-11-14 |
| 2023-06-30 | $422.75K 10-K · filed 2024-09-25 |
| 2023-03-31 | $267.80K 10-Q · filed 2023-05-11 |
| 2022-12-31 | $532.91K 10-Q · filed 2023-02-10 |
| 2022-09-30 | $601.67K 10-Q · filed 2022-11-10 |
| 2022-06-30 | $1.03M 10-K · filed 2023-09-22 |
| 2021-06-30 | $1.67M 10-K · filed 2022-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |